

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*



**COMPLETE IF KNOWN**

Application Number	10/573,926 10573926 - GAU: 1632
Filing Date	March 30, 2006
First Named Inventor	John W. Hess
Group Art Unit	to be assigned 1632
Examiner Name	to be assigned Anne-Marie Falk, Ph.

Shee

1

10

Attorney Docket Number

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner  
Signature

/Anne Marie Falk/

**Date Considered**

09/22/2009

\* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22312-1450. Patent and Trademark Office, U.S. Patent and Trademark Office, 1450 K Street, N.W., Washington, D.C. 20591-1450. (703) 553-3700. (800) 742-9106. (703) 553-3700. (800) 742-9106.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AMF/

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

APR 3 2007  
(use as many sheets as necessary)

Sheet 1

of

2

## COMPLETE IF KNOWN

Application Number	10/573,926 10573926 - GAU: 1632
Filing Date	March 30, 2006
First Named Inventor	John W. Hess
Group Art Unit	to be assigned
Examiner Name	to be assigned

Attorney Docket Number 21394YP

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	CO1	Bock et al. "Bradykinin antagonists: new opportunities", Current Opinion in Chemical Biology", Vol. 4, pp 401-406 (2000)
	C02	Bonaventure et al. "Humanization of Mouse 5-Hydroxytryptamine 1B Receptor Gene by Homologous Recombination: In Vitro and In Vivo Characterization", Molecular Pharmacology, Vol. 56, pp 54-67 (1999)
	C03	Dray and Perkins, "Bradykinin and Inflammatory Pain", TINS, Vol. 16, No. 3, pp 99-10 (1993)
	C04	GenBank Accession No. BC034705 (2002)
	C05	GenBank Accession No. NM_007539 (2002)
	C06	Hess et al. "The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors", Immunopharmacology, Vol. 33, pp 1-8 (1996)
	C07	Hess et al. "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor", Biochemical and Biophysical Research Communications, Vol. 184, No. 1, pp 260-268 (1992)
	C08	Jones et al. "Molecular characterisation of cloned bradykinin B1 receptors from rat and human", European Journal of Pharmacology, Vol. 374, pp 423-433 (1999)
	C09	MacNeil et al. "Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor", Biochimica et Biophysica Acta, Vol. 1264, pp 223-228 (1995)
	C10	McEachern et al. "Expression cloning of a rat B2 bradykinin receptor", Proc. Natl. Acad. Sci. USA Vol. 88, pp 7724-7728 (1991)
	C11	Menke et al. "Expression Cloning of a Human B1 Bradykinin Receptor", Journal of Biological Chemistry, Vol. 269, No.34, Issue of August 26, pp 21583-21586 (1994)
	C12	Milstone et al. "Simultaneous Cre Catalyzed Recombination of Two Alleles to Restore Neomycin Sensitivity and Facilitate Homozygous Mutations", Nucleic Acids Research, Vol. 27, No. 15, pp 1-3 (1999)
	C13	Pesquero et al. "Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors", Proc. Natl. Acad. Sci. USA, Vol. 97, No. 14, pp 8140-8145 (2000)
	C14	Pesquero et al. "Molecular Cloning and Functional Characterization of a Mouse Bradykinin B1 Receptor Gene", Biochemical and Biophysical Research Communications, Vol. 220, pp 219-225 (1996)
	C15	Proud and Kaplan, "Kinin Formation: Mechanisms and Role in Inflammatory Disorders", Annual Review Immunology, Vol. 6, pp 49-83 (1988)

Examiner Signature

/Anne Marie Falk/

Date Considered

09/22/2009

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AMF/